Skip to main content
. Author manuscript; available in PMC: 2019 Jan 1.
Published in final edited form as: Hypertension. 2017 Nov 13;71(1):87–94. doi: 10.1161/HYPERTENSIONAHA.117.09843

Figure 1.

Figure 1

Investigation of route of nanoparticle administration. A) In vivo near-infrared fluorescence images of nanoparticle-encapsulated dye in mice 72 hours following administration via different administration routes: IV=intravenous tail vein; RO=intravenous retroorbital; IP=intraperitoneal; SQ=subcutaneous flank; PO=per os, oral gavage. B) Fluorescence efficiency of renal nanoparticle localization at indicated timepoints following injection, for intravenous administration routes. Data represent mean ± standard deviation, N = 3. C) Average fluorescence efficiency of mouse kidneys, measured after sacrifice 72 hours after animals were administered with nanoparticles via different routes. Data are background subtracted and represent mean ± standard deviation, N = 3.